Medicus Pharma Gains FDA Clearance for Phase 2b Prostate Cancer Trial
On February 10, 2026, Medicus Pharma received FDA clearance to proceed with a Phase 2b clinical trial evaluating its lead prostate cancer therapy across U.S. sites. The study will assess safety, tolerability and preliminary efficacy endpoints, providing key data to support design of a pivotal Phase 3 trial.
1. FDA Clearance
On February 10, 2026, Medicus Pharma received FDA clearance for its investigational new drug application, allowing initiation of its Phase 2b clinical trial in prostate cancer. The decision confirms regulatory support for advancing its lead therapeutic candidate to a more rigorous efficacy assessment.
2. Planned Phase 2b Study
The upcoming trial will enroll prostate cancer patients across multiple U.S. centers to evaluate safety, tolerability and anti-tumor activity of the company’s lead candidate. Results are expected to inform dosing strategies and pivotal Phase 3 study design.